Aragona 2005.

Study characteristics
Methods	Design: parallel Duration: 8 weeks Assessment: baseline and post‐intervention Country: Italy
Participants	Pain condition: somatoform DSM‐IV‐TR pain disorder Population: people with somatoform DSM‐IV‐TR pain disorder  Minimum pain intensity: no Inclusion criteria People with DSM‐IV‐TR pain disorder as assessed by clinicians. Pain had to have no direct, organic explanation, and participants had to have presence of psychological factors that could have influenced consent/clinical course of pain. Exclusion criteria Pregnancy Medical conditions of clinical importance Diagnosis of another mental health condition Total participants randomised: 35 Age in years (mean, SD): NR Gender: 21/35 were female Pain duration: NR
Interventions	Citalopram Fixed dose of 40 mg/day (2 x 20 mg doses) Titrated over 4 days SSRI Reboxetine Fixed dose of 8 mg/day (2 x 4 mg doses) Titrated over 4 days NaRI
Outcomes	Pain intensity Depression AEs SAEs Withdrawal
Missing data methods	LOCF
Funding source	NR
Conflicts of interest	NR
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were randomly assigned using random tables
Allocation concealment (selection bias)	Unclear risk	No information given
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No information given regarding appearance of medications
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information given regarding appearance of medications
Incomplete outcome data (attrition bias) All outcomes	High risk	Used LOCF as imputation method, high attrition Attrition: Total: 6/35 (17.1%) Citalopram 40 mg: 6/17 (35.3%) Reboxetine 8 mg: 9/18 (50.0%)
Selective reporting (reporting bias)	Unclear risk	No protocol or trial registration found
Other bias	Low risk	No other sources of bias were identified